PMVP · PMV Pharmaceuticals, Inc.
$1.06
-0.04 (-3.64%)
At close · Jul 29
Market Cap
$57.06M
Shares
53.33M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $1,665,191 |
| Robert Ticktin | COO | $861,206 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $4,760,281 |
| Deepika Jalota | Chief Development Officer | $1,929,014 |
| Michael Carulli | CFO | $1,379,515 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $2,209,795 |
| Winston Kung | CFO | $1,260,259 |
| Deepika Jalota | Chief Development Officer | $1,097,198 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $3,576,440 |
| Winston Kung | CFO | $1,768,476 |
| Deepika Jalota | Chief Development Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $3,541,855 |
| Winston Kung | CFO | $1,665,259 |
| Leila Alland | Chief Medical Officer | $1,400,292 |
| Deepika Jalota | Chief Development Officer | $1,026,863 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Leila Alland | Chief Medical Officer | $1,674,649 |
| David H. Mack | CEO | $1,314,113 |
| Winston Kung | CFO | $825,365 |
| Deepika Jalota | Chief Development Officer | $532,673 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David H. Mack | CEO | $628,110 |
| Winston Kung | CFO | $562,440 |
| Deepika Jalota | Chief Development Officer | $517,138 |